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Dyslipidemia among HIV/AIDS patients
receiving antiretroviral therapy: A prospective
observational study
A. Biswas ∗, K. Suneesh, P. Sohal, S. Sharma
AIIMS, New Delhi, India
Background: Dyslipidemia due to Antiretroviral Therapy
among HIV/AIDS increases cardiovascular risk and high morbidity
and mortality. This study was conducted to estimate the incidence
of dyslipidemia for prevention, control and proper management to
reduce cardiovascular risks and death.
Methods & Materials: We conducted a prospective observa-
tional study among HIV/AIDS patients those who were initiated
Antiretroviral Therapy (ART) medication. The US NCEP III (National
Cholesterol Education Program– III) guidelineswere used to deﬁne
dyslipidemia. Fasting Lipid proﬁle was estimated at 0 month, 6th
month and at 12th month from the date of enrolment. Our primary
observationwas to determine the change in fasting serum lipid lev-
els higher than border line as per the NCEP-III guideline. We used
linear regression to experience change in lipid levels controlling for
base line lipid values, demographic and clinical characteristics.
Results: We enrolled 135 patients for the study. There were
65.9% (89) male,34.1% (46) female, mean age 37 years(SE-0.8)
and 6.7% (9) were unmarried. Most of the patients 63.7% (86)
had heterosexual transmission. 22.96% (31) had unknown history
and 12.6% (17) through blood transfusion. In our study 3 drugs
combination ART was given and 30% (40) of the these were receiv-
ing Stavudine based ART regimen(d4T+3TC+NVP/EFV), 70%(95)
Zydovudine based regimen (AZT+3TC+NVP/EFV). Overall inci-
dence of dyslipidemia (high total cholesterol > 239mg/dl) was 25%
(26). Among Stavudine based regimen 15%(6) had incidence of
dyslipidemia (high cholesterol). Incidence of dyslipidemia was
detected among 22.8% (23) due to high LDL-C (>159mg/dl). Among
Stavudine based regimen 17.5% (7) of patients developed dys-
lipidemia (high LDL-C). High triglyceride (TG>299mg/dl) was
detected among 8.2% (9). Totalmortalitywas 6.6% (9), lost to follow
up were 11.8% (16). At 6 months of follow up 6 (5%) patients devel-
oped dyslipidemia (high cholesterol) and were referred for the
management with lipid lowering agents.
Conclusion: Incidence ofDyslipidemia at 6thmonthwas 5% and
at 12th month was 25% .The incidence of high LDL-C was 22.8%,
among Stavudine regimen was 17.5% and high TG was 8.2% over
one year with ART. However in our study Stavudine based regimen
was found to have 15% incidence of dyslipidemia.
http://dx.doi.org/10.1016/j.ijid.2014.03.698
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Ion PGM deep sequencing improves mutation
detection in infants who failed PMTCT
R.G. Fisher1,∗, S. Kosakovsky Pond2, B. Murrel2, R.
Slabbert1, C. Edson3, M.F. Cotton4, R. Haubrich2,
D. Smith2, G. van Zyl4
1 Stellenbosch University, Cape Town, South Africa
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Background: In children who are HIV-infected despite a nevi-
rapine (NVP) containing HIV-PMTCT regimen, bulk sequencing
reliably detects major variant drug resistance mutations (DRM)
(>20-30% of viral population). Ion Personal Genome Machine
(Ion PGM) deep sequencing, combined with rigorous analysis and
error correction may be an alternative with increased sensitivity,
enabling detection of potentially clinically signiﬁcantminor DRM
variants.
Methods & Materials: We conducted a retrospective study
in 20 HIV-infected infants, born from Oct 2006 to Oct 2009,
who failed PMTCT (maternal AZT from 28 weeks gestation, intra
partum NVP, and neonatal single doseNVP with 7 days, AZT).
Baseline specimens, before combination antiretroviral therapy
(cART), werebulk sequenced using in-house genotyping. For Ion
PGM sequencing, extractedRNA was reverse transcribed using
random pentadecamers, before ampliﬁcation through 14 pre-
and 7-nested PCR’s. PCR products were enzymatically fragmented
and ligated to indexingbar-codes, followed by enrichment and
sequencing. Reads wereﬁltered using quality scores, aligned to a
subtype C reference sequence using a codon-aware versionof the
Smith-Waterman algorithm, correcting for homopolymer errors. A
mixture of multinomials probabilisticmodel was used to distin-
guish sequencing error from true minor variants with posterior
probabilities≥99.99%, excluding bases identiﬁed as errors. For each
sample, we computed the mean of all pairwise Tamura-Nei 93 dis-
tances between reads with at least 100 overlapping base pairs to
quantify nucleotidediversity.
Results: Median age was 3.5 (IQR: 2.4-4.8) months, median
viral load and CD4% was 5.8 log copies/ml (IQR: 5.1-6.3) and
26% (IQR: 22-35%) respectively; 65% were female. Median cov-
erage for reverse transcriptasepositions 40 - 230 (including all
major ARV-DRM) was 31000 (IQR: 20400-39500) and median
intra-samplenucleotide diversity was 0.6% (IQR: 0.4%-1.2%). Bulk
sequencing detected one NNRTI DRM in 2 patients: K103N and
Y181I. Ion PGM detected DRM at a frequency ≥ 2% in 2 addi-
tional patients: K103N (22%) andY181C (2%), respectively, and
minor variant Y181C (3.7%) in addition to K103N (detected
by bulk sequencing) in a third. No AZT-associated DRM were
detected.
Conclusion: Only 20% of infants had NVP associated DRM
≥2% frequency by deep sequencing. When combined with a
bioinformatic pipeline, Ion PGM deep sequencing detected more
NVP-DRMs in infants with PMTCT exposure than bulk sequenc-
ing. Thismethod could be valuable when considering recycling
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Low number of second-line HAART switched
patients among children in Buikwe, Uganda,
community-based health program
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Background: About 20% of all children on antiretroviral ther-
apy (ART) exhibit resistance to 1-3 antiretrovirals in 2-5 years after
starting and require therefore 2nd line treatment. Purpose of this
study was to assess the proportion and risk factors of second line
ARV in children who failed on 1st line ART in Buikwe, Uganda.
Methods & Materials: One hundred and sixty two (n=162)
patients who were enrolled into the program since October 2012
to June 2013, into the community-based health program run by St.
John Paul′s Paediatric Clinic in Buikwe, Uganda were analysed to
assess risk factors, demographic and clinical characteristics. After
two years, only those (n=107) patients who were still on ART were
included for analysis.
Results: Majority of patients enrolled in the program were
still on 1st line therapy after 2 years of follow-up (104;
97,2%). Regarding regimens, 38 (36,5%) are receiving azi-
dothymidine/lamivudine/nevirapine (AZT/3TC/NVP), 31 (29,8%)
receiving tenofovir/3TC/efavirenz (TDF/3TC/EFV), 9 (8,7%) receiv-
ing AZT/3TC/EFV and one (1%) receiving TDF/3TC/NVP. Three of
107 (2,8%) children had to switch to 2nd line ART due to clinical
(2) and/or immunological (1) failure, both accompanied with the
increase of viral load. Non-compliance was the commonest risk
factor in all cases.
Conclusion: Failure rate in children and adolescents on ART
in Uganda was very low after 2 years of follow up. Majority of
patients on 1st line receive AZT/3TC/NVP or AZT/3TC/EFV and the
rest TDF/3TC/EFV or TDF/3TC/NVP. Noncompliance was the major
risk factor, followed by the failure of 1st line therapy. droup out
from the community, and the change of treatment centre.
http://dx.doi.org/10.1016/j.ijid.2014.03.700
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Quality audit of rapid HIV diagnostic processes
and outcomes in selected health facilities in the
central region of Ghana
N.A.A. Ntim ∗, K.M. Nyarko
School of Public Health, University of Ghana, Accra,
Ghana
Background: Human immunodeﬁciency virus (HIV) is one of
the leading infectious killers worldwide. An estimated 34.2 mil-
lion people worldwide were living with HIV in 2011 with about
60% of the HIV infections occur in sub-Saharan Africa. Testing to
know one’s HIV status is a key intervention to the prevention and
early treatment of cases. The introduction of rapid HIV test kits has
increased access to HIV testing. The rapid HIV test although easy to
do after proper training by both laboratory andnon-laboratory per-
sons requires a quality assurance system in place to prevent errors
and ensure the accuracy and reliability of test results. This study
set out to compare rapid HIV test results from both laboratory and
non-laboratory staff, to assess the knowledge of the testing staff on
the dry tube specimen proﬁciency testing (DTSPT) scheme and to
assess the competency of the testing staff.
Methods & Materials: We conducted a cross sectional study on
240 pregnant women who had been rapidly tested for HIV in four
antenatal clinics in the Central Region of Ghana. Participants were
enrolled after informed consenting. Venous blood sample (3ml)
was taken and retested in the laboratory using the same rapid HIV
test (First response and Oraquick ½) kits. A questionnaire on the
dry tube specimen proﬁciency testing scheme was administered to
all testing staff. A site audit checklist was used to assess staff com-
petency. Using Excel and SPSS, the sensitivity, speciﬁcity, positive
and negative predictive values, frequencies and proportions were
calculated.
Results:High concordance between laboratory (100%) and non-
laboratory (99.6%) rapid HIV test results. There was one (0.4%)
discordant test result between the two groups. Majority (80%) of
both groups of testing staff did not have any knowledge of the
dried tube specimen proﬁciency testing scheme. Staffs (100%)were
competent to perform and interpret test results. Three (75%) of the
health facilities did not have rapid test kits to provideVCT to clients.
Conclusion: No signiﬁcant difference between test performed
by laboratory andnon-laboratory persons. Knowledge of theDTSPT
scheme was poor. Staffs were competent to use the rapid HIV test
kits correctly.
http://dx.doi.org/10.1016/j.ijid.2014.03.701
